Please select the option that best describes you:
Topics:
Breast Cancer • Radiation Oncology
How do you approach breast hypofractionation RNI with the results of the Skagen Trial 1?
Do the results from the Skagen Trial 1, presented at ESTRO 2025, showing worse all-cause mortality and breast cancer-specific mortality in the hypofrac arm, warrant caution with using this approach, especially in light of the positive data from RT-CHARM?
Answer from: Radiation Oncologist at Community Practice
There are multiple prospective/randomized studies showing non-inferiority for complications or cancer outcome with hypofractionation and RNI, including Wang et al., PMID 30711522, HypoG-01, FABREC, RT-CHARM, and the subset arm of STARTb. The primary endpoint of DKSG was also lymphedema, which was no...
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
This is a great question. Was coverage of the internal mammary nodes suboptimal, perhaps due to perceived risk to the heart with the higher dose per fraction?